FDA Wants Fast Turnaround In Assessing Opioid REMS' Effectiveness
This article was originally published in The Pink Sheet Daily
The agency tells companies to submit proposals in 120 days, and expects to have the REMS in place by the beginning of 2012. The first assessment would be due at six months.
You may also be interested in...
Prescriber training courses to be provided through continuing medical education venues are to be available by March 1, 2013. Changes from the draft are subtle, but indicate FDA’s focus on preventing incorrect use of the high-dosage narcotics and protecting patients.
By the third year of continuing medical education efforts, FDA expects 60% of those who wrote a prescription for a long-acting/extended-release opioid in 2011 to receive training.
An FDA-convened panel of experts finds no single best question format for ascertaining patients’ and prescribers’ knowledge about drug risks learned through Risk Evaluation and Mitigation Strategies.